FDA’s final reference document on expedited regulatory pathways clarifies several aspects of the “breakthrough therapy” program, including the types of “preliminary clinical evidence” that would support a designation.
The guidance, “Expedited Programs for Serious Conditions – Drug and Biologics,” defines what the agency means by preliminary clinical evidence under the breakthrough program and includes examples of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?